論文 - 海北 幸一
-
JCS/CVIT/JCC 2023 Guideline Focused Update on Diagnosis and Treatment of Vasospastic Angina (Coronary Spastic Angina) and Coronary Microvascular Dysfunction. 査読あり
Hokimoto S, Kaikita K, Yasuda S, Tsujita K, Ishihara M, Matoba T, Matsuzawa Y, Mitsutake Y, Mitani Y, Murohara T, Noda T, Node K, Noguchi T, Suzuki H, Takahashi J, Tanabe Y, Tanaka A, Tanaka N, Teragawa H, Yasu T, Yoshimura M, Asaumi Y, Godo S, Ikenaga H, Imanaka T, Ishibashi K, Ishii M, Ishihara T, Matsuura Y, Miura H, Nakano Y, Ogawa T, Shiroto T, Soejima H, Takagi R, Tanaka A, Tanaka A, Taruya A, Tsuda E, Wakabayashi K, Yokoi K, Minamino T, Nakagawa Y, Sueda S, Shimokawa H, Ogawa H, Japanese Circulation Society and Japanese Association of Cardiovascular Intervention and Therapeutics and Japanese College of Cardiology Joint Working Group
Circulation journal : official journal of the Japanese Circulation Society 2023年3月
-
Japanese high bleeding risk criteria status predicts low thrombogenicity and bleeding events in patients undergoing percutaneous coronary intervention. 査読あり
Nakanishi N, Kaikita K, Ishii M, Kuyama N, Tabata N, Ito M, Yamanaga K, Fujisue K, Hoshiyama T, Kanazawa H, Hanatani S, Sueta D, Takashio S, Arima Y, Araki S, Usuku H, Nakamura T, Yamamoto E, Soejima H, Matsushita K, Tsujita K
Cardiovascular intervention and therapeutics 2023年3月
-
Relationship between coronary artery calcium score and bleeding events after percutaneous coronary intervention in chronic coronary syndrome. 査読あり
Komaki S, Ishii M, Kaichi R, Takae M, Mori T, Toida R, Kurogi K, Matsuura Y, Yamamoto N, Tsujita K, Tsuruda T, Kaikita K
Heart and vessels 2023年2月
-
Analysis of Mechanisms for Increased Blood Pressure Variability in Rats Continuously Infused with Angiotensin II. 査読あり
Jiang D, Matsuzaki M, Kawagoe Y, Kitamura K, Tsuruda T, Kaikita K, Asada Y, Kato J
Journal of the renin-angiotensin-aldosterone system : JRAAS 2023 4201342 2023年1月
-
Utility of the Total Thrombus-Formation Analysis System as a Tool for Evaluating Thrombogenicity and Monitoring Antithrombotic Therapy in Pediatric Fontan Patients. 査読あり
Matsuo O, Ishii M, Kaikita K, Morinaga J, Miyamura F, Matsumoto S, Tsujita K, Nakamura K
Pediatric cardiology 2022年12月
-
Differential effects of overweight/obesity depending on the severity of heart failure complicating acute myocardial infarction in Japan. 査読あり
Matsushita K, Kojima S, Hirakawa K, Tabata N, Ito M, Yamanaga K, Fujisue K, Hoshiyama T, Hanatani S, Sueta D, Kanazawa H, Takashio S, Arima Y, Araki S, Usuku H, Suzuki S, Yamamoto E, Nakamura T, Soejima H, Kaikita K, Tsujita K
Progress in cardiovascular diseases 2022年12月
-
Rivaroxaban Monotherapy in Atrial Fibrillation and Stable Coronary Artery Disease Across Body Mass Index Categories. 査読あり
Ishii M, Kaikita K, Yasuda S, Akao M, Ako J, Matoba T, Nakamura M, Miyauchi K, Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H, Tsujita K, AFIRE Investigators
JACC. Asia 2 ( 7 ) 882 - 893 2022年12月
-
Rivaroxaban Monotherapy in Patients With Atrial Fibrillation and Coronary Stenting at Multiple Vessels or the Left Main Trunk: The AFIRE Trial Subanalysis. 査読あり
Ishii M, Akao M, Yasuda S, Kaikita K, Ako J, Matoba T, Nakamura M, Miyauchi K, Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H, AFIRE Investigators.
Journal of the American Heart Association 11 ( 21 ) e027107 2022年10月
-
Optimal Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Focused Review on High Bleeding Risk. 査読あり
Matsuura Y, Moribayashi K, Kaikita K
Journal of atherosclerosis and thrombosis 29 ( 10 ) 1409 - 1420 2022年10月
-
Validation of the obesity paradox by body mass index and waist circumference in patients undergoing percutaneous coronary intervention. 査読あり
Shirahama Y, Tabata N, Sakamoto K, Sato R, Yamanaga K, Fujisue K, Sueta D, Araki S, Takashio S, Arima Y, Hokimoto S, Sato K, Sakamoto T, Nakao K, Shimomura H, Matsumura T, Tayama S, Fujimoto K, Oshima S, Nakamura S, Tsunoda R, Hirose T, Kikuta K, Sakaino N, Yamamoto N, Kajiwara I, Suzuki S, Yamamoto E, Kaikita K, Matsushita K, Tsujita K, Kumamoto Intervention Conference Study (KICS) Investigators.
International journal of obesity (2005) 46 ( 10 ) 1840 - 1848 2022年10月
-
Bystander-witnessed cardiopulmonary resuscitation by nonfamily is associated with neurologically favorable survival after out-of-hospital cardiac arrest in Miyazaki City District. 査読あり
Tsuruda T, Hamahata T, Endo GJ, Tsuruda Y, Kaikita K
PloS one 17 ( 10 ) e0276574 2022年10月
-
Fujisue K, Yamamoto E, Sueta D, Arima Y, Hirakawa K, Tabata N, Ishii M, Ito M, Yamanaga K, Hanatani S, Hoshiyama T, Kanazawa H, Takashio S, Araki S, Usuku H, Nakamura T, Soejima H, Kaikita K, Kawano H, Matsushita K, Tsujita K
Journal of atherosclerosis and thrombosis 29 ( 9 ) 1285 - 1294 2022年9月
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：一般社団法人 日本動脈硬化学会
<b>Aims: </b>Royal jelly, a creamy substance secreted by honeybees, has been reported to have beneficial effects against dyslipidemia and metabolic syndrome. However, the effects of royal jelly on atherogenesis remain unknown. Hence, we prospectively evaluated whether royal jelly augments vascular endothelial function, which can reflect early atherogenesis, in healthy volunteers.<b> </b><b>Methods: </b>This was a single-center, double-blind, 1:1 randomized placebo-controlled study conducted from October 2018 to December 2019. A total of 100 healthy volunteers were randomly assigned to receive either royal jelly 690 mg or placebo daily for 4 weeks. The primary endpoint was augmentation in vascular endothelial function as assessed using the change in the reactive hyperemia peripheral arterial tonometry index (RH-PAT) index, and the secondary endpoints were the changes in liver function and lipid profiles between baseline and 4 weeks after enrollment.<b> </b><b>Results: </b>The mean age of the participants was 35.0±9.3 years in the placebo group and 36.1±9.1 years in the royal jelly groups; 45% and 50% of the placebo and the royal jelly groups, respectively, were male. The percentage relative change in the RH-PAT index was significantly higher in the royal jelly group than in the placebo group (21.4%±53.1% vs. 0.05%±40.9%, <i>P</i>=0.037). The percentage relative changes in alanine aminotransferase and γ-glutamyl transpeptidase were significantly lower in the royal jelly group than in the placebo group (alanine aminotransferase: −6.06%±22.2% vs. 11.6%±46.5%, <i>P</i>=0.02; γ-glutamyl transpeptidase: −3.45%±17.8% vs. 4.62%±19.4%, <i>P</i>=0.045). Lipid profiles were not significantly different between the two groups.<b> </b><b>Conclusions: </b>Royal jelly might have antiatherogenic property by improving vascular endothelial function. It also augmented liver functions in healthy volunteers.
DOI： 10.5551/jat.63044
-
Apical flow and wall motion dynamics in left ventricular outflow obstruction: a case report. 査読あり
Misumi I, Sato K, Nagano M, Haba K, Ohba K, Kaikita K, Tsujita K
Journal of echocardiography 20 ( 3 ) 178 - 179 2022年9月
-
診療科訪問形式による「品質管理講習会」開催の試みについて 査読あり
森田ひとみ, 柳田俊彦, 板井孝壱郎, 岩江荘介, 海北幸一, 竹島秀雄
薬理と治療（JPT）日本臨床試験学会雑誌 50 ( suppl. 1 ) s62 - s66 2022年8月
担当区分：筆頭著者 記述言語：日本語 掲載種別：研究論文（学術雑誌）
-
Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial. 査読あり
Naito R, Miyauchi K, Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H, AFIRE Investigators.
JAMA cardiology 7 ( 8 ) 787 - 794 2022年6月
-
Rivaroxaban Underdose for Atrial Fibrillation with Stable Coronary Disease: The AFIRE Trial Findings. 査読あり
Arashi H, Yamaguchi J, Hagiwara N, Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, Miyauchi K, Kimura K, Hirayama A, Matsui K, Ogawa H
Thrombosis and haemostasis 122 ( 9 ) 1584 - 1593 2022年6月
-
Impact of statins in patients with vasospastic angina: A multicenter registry study of the Japanese Coronary Spasm Association. 査読あり
Mori H, Takahashi J, Sato K, Miyata S, Takagi Y, Tsunoda R, Sumiyoshi T, Matsui M, Tanabe Y, Sueda S, Momomura SI, Kaikita K, Yasuda S, Ogawa H, Shimokawa H, Suzuki H, Japanese Coronary Spasm Association.
Journal of cardiology 80 ( 3 ) 226 - 231 2022年5月
-
Takotsubo cardiomyopathy after vaccination for coronavirus disease 2019 in a patient on maintenance hemodialysis. 査読あり
Toida R, Uezono S, Komatsu H, Toida T, Imamura A, Fujimoto S, Kaikita K
CEN case reports 11 ( 2 ) 220 - 224 2022年5月
-
Nakanishi N., Kaikita K., Ishii M., Kuyama N., Tabata N., Ito M., Yamanaga K., Fujisue K., Hoshiyama T., Kanazawa H., Hanatani S., Sueta D., Takashio S., Arima Y., Araki S., Usuku H., Nakamura T., Suzuki S., Yamamoto E., Soejima H., Matsushita K., Tsujita K.
Nutrition, Metabolism and Cardiovascular Diseases 32 ( 5 ) 1227 - 1235 2022年5月
担当区分：責任著者 記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Nutrition, Metabolism and Cardiovascular Diseases
Background and aims: Although antithrombotic treatments are established for coronary artery disease (CAD), they increase the bleeding risk, especially in malnourished patients. The total thrombus-formation analysis system (T-TAS) is useful for the assessment of thrombogenicity in CAD patients. Here, we examined the relationships among malnutrition, thrombogenicity and 1-year bleeding events in patients undergoing percutaneous coronary intervention (PCI). Methods and results: This was a retrospective analysis of 300 consecutive CAD patients undergoing PCI. Blood samples obtained on the day of PCI were used in the T-TAS to compute the thrombus formation area under the curve. We assigned patients to two groups based on the geriatric nutritional risk index (GNRI): 102 patients to the lower GNRI group (≤98), 198 patients to the higher GNRI group (98<). The primary endpoint was the incidence of 1-year bleeding events defined by Bleeding Academic Research Consortium criteria types 2, 3, or 5. The T-TAS levels were lower in the lower GNRI group than in the higher GNRI group. Kaplan-Meier analysis showed worse 1-year bleeding event-free survival in the lower GNRI group compared with the higher GNRI group. The combined model of the GNRI and the Academic Research Consortium for High Bleeding Risk (ARC-HBR) had good calibration and discrimination for bleeding risk prediction. In addition, having a lower GNRI and ARC-HBR positivity was associated with 1-year bleeding events. Conclusion: A lower GNRI could reflect low thrombogenicity evaluated by the T-TAS and determine bleeding risk in combination with ARC-HBR positivity.
-
Increased thrombogenicity is associated with revascularization outcomes in patients with chronic limb-threatening ischemia. 査読あり
Kuyama N, Kaikita K, Ishii M, Mitsuse T, Nakanishi N, Fujisue K, Otsuka Y, Hanatani S, Sueta D, Takashio S, Araki S, Yamamoto E, Matsushita K, Tsujita K
Journal of vascular surgery 76 ( 2 ) 513 - 522 2022年4月